Details for Patent: 11,110,081
✉ Email this page to a colleague
Which drugs does patent 11,110,081 protect, and when does it expire?
Patent 11,110,081 protects ENVARSUS XR and is included in one NDA.
This patent has thirty patent family members in sixteen countries.
Summary for Patent: 11,110,081
| Title: | Tacrolimus for improved treatment of transplant patients |
| Abstract: | An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form. |
| Inventor(s): | Gordon; Robert D. (Sandy Springs, GA), Holm; Per (Vanlose, DK), Lademann; Anne-Marie (Klampenborg, DK), Norling; Tomas (Lyngby, DK) |
| Assignee: | VELOXIS PHARMACEUTICALS, INC. (Cary, NC) |
| Application Number: | 17/085,291 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 11,110,081
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,110,081
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | PA200700783 | May 30, 2007 |
| Denmark | PA200701573 | Nov 7, 2007 |
International Family Members for US Patent 11,110,081
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 081520 | ⤷ Sign Up | |||
| Canada | 2688381 | ⤷ Sign Up | |||
| Canada | 2729948 | ⤷ Sign Up | |||
| Denmark | 2167033 | ⤷ Sign Up | |||
| Denmark | 2575769 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 027869 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
